Ethics submission for Ox-1 Phase 1 study

AI SummaryClose X

TheraCryf submitted an ethics application to the Bellberry Human Research Ethics Committee in Australia in November 2026 via its wholly owned subsidiary TheraCryf Australia Pty Ltd to initiate a first-in-human Phase 1 study of its orexin-1 (Ox-1) antagonist; the submission follows completion of the preclinical package including final reporting of 28-day regulatory toxicology studies in two species. Following anticipated HREC approval the company will file a Clinical Trial Notification with the TGA and continues to target regulatory approvals by the turn of this calendar year.

Disclaimer*

UK 100